Establishment Labs Signals Strong Momentum in Earnings Call

Establishment Labs Holdings ((ESTA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Establishment Labs’ latest earnings call struck a notably upbeat tone, as management highlighted strong revenue growth, expanding margins, and renewed profitability, all anchored by a rapid U.S. launch and accelerating demand for its minimally invasive platform. While executives acknowledged higher operating expenses, increased leverage, and some external uncertainties, they framed these as manageable risks against a clear path toward sustained cash-flow positivity.

Robust Top-Line Growth and Upgraded Outlook

Establishment Labs reported first-quarter 2026 revenue of $59.9 million, a 44.7% year-over-year increase that outpaced prior expectations and set the stage for a higher full-year target. Management now sees 2026 revenue between $266.5 million and $268.5 million, implying roughly 26% to 27% growth versus 2025 as momentum builds across core markets.

U.S. Launch Outperforms, Driving Mix Shift

The U.S. market has quickly become a growth engine, with first-quarter revenue of $19.6 million representing 32.7% of company sales and surging 216% year over year. Weekly orders hit new highs and average order sizes have climbed about 30% since late 2025, supporting management’s view that the U.S. will contribute more than 30% of total revenue this year versus about 22% last year.

Minimally Invasive Platform Gains Traction

The company’s minimally invasive platform delivered $9.1 million in first-quarter revenue, prompting an upward revision to 2026 guidance for this business to more than $35 million from a prior $30 million target. Over 260 U.S. surgeons are already certified, beating the full-year goal early, and patient survey data show high satisfaction, minimal disruption, and strong willingness to pay a premium for the procedure.

Profitability Metrics Turn the Corner

Gross margin expanded by 350 basis points to 70.7% in the quarter, reflecting improved scale and favorable mix, while adjusted EBITDA swung to a $1.2 million profit from a $12.1 million loss a year earlier. This marks the third consecutive quarter of positive adjusted EBITDA, and management signaled confidence that each remaining quarter in 2026 will remain in the black.

Operational Scale and Market Adoption Strengthen

Establishment Labs now serves more than 1,700 accounts globally, underscoring growing penetration and recurring demand across regions. Surveys indicate that 78% of surgeons encounter patients asking for a specific brand and, when that happens, Motiva is requested 93% of the time, a dynamic the company links to elevated brand awareness and larger average orders.

Clinical Outcomes Underpin Market Differentiation

Management emphasized safety data as a key competitive advantage, citing capsular contracture and claim rates below 1% based on FDA trial results and more than 49,000 warranties sold. By contrast, they noted competitor complication rates in some FDA trials reaching roughly 20%, positioning Motiva’s profile as a meaningful driver of surgeon preference and patient trust.

Balance Sheet Moves Bolster Liquidity

The company refinanced its debt facility, boosting availability from $225 million to $265 million and securing a stated 8.75% rate with the flexibility to pay interest in kind to preserve cash. About $6 million of proceeds flowed in during the quarter, and with $68.1 million of cash on hand, management stated they have sufficient liquidity to bridge the business to cash-flow breakeven in the second half of 2026.

Pipeline and R&D Expand Future Opportunities

Beyond the current aesthetic franchise, Establishment Labs is working to broaden its addressable market with a series of regulatory and product initiatives, including a U.S. submission for breast reconstruction indications and new biosensing capabilities such as the Zen temperature platform. Additional programs like Ergo2, GEM for gluteal augmentation, smaller implant sizes, and planned regulatory filings in Canada are expected to support longer-term growth rather than near-term guidance.

Cash Usage and Operating Spend Remain Elevated

Despite improving profitability, cash fell by $7.5 million in the quarter to $68.1 million, and management warned of higher outflows in the second quarter due to an acquisition-related payment, incentive compensation, and ongoing U.S. investments. Operating expenses remain sizable, with first-quarter SG&A at $43.6 million and full-year operating costs projected at $195 million to $200 million as the company prioritizes scaling commercial infrastructure.

Debt Structure and PIK Interest Add Leverage Risk

The enlarged $265 million debt facility and PIK interest feature provide meaningful near-term flexibility, including more than $5 million per quarter of potential cash interest relief, but they also increase future obligations. Management acknowledged that if growth or cash conversion were to slow, higher leverage and accrued interest could constrain options, making execution on revenue and margin targets especially critical.

Supply, Macro, and Timing Uncertainties Persist

Silicone supply is secured for 2026 under the existing NuSil contract, but negotiations for later years are ongoing and could expose the company to cost inflation once current terms expire. Geopolitical volatility, including a pause in orders from the Middle East and surcharges on outbound freight, along with seasonal patterns and uncertain timing for certain regulatory approvals, all introduce variability around the otherwise strong growth trajectory.

Guidance Signals Confidence in Sustained Momentum

Management’s raised 2026 revenue outlook, higher minimally invasive platform forecast, and guidance for full-year gross margins above 71% reflect clear confidence in demand and pricing. They expect adjusted EBITDA to remain positive in every quarter and are targeting cash-flow positivity in the second half of 2026, with second-quarter EBITDA projected to roughly double the first quarter and U.S. revenue set to exceed 30% of total sales for the year.

Establishment Labs’ earnings call painted the picture of a company transitioning from growth-at-any-cost toward a more balanced model combining rapid top-line expansion with improving profitability and a clearer cash-flow path. Investors will be watching whether the company can sustain U.S. momentum, manage elevated spending, and navigate external risks, but for now the narrative is dominated by accelerating adoption, strong margins, and rising confidence in the long-term strategy.